Company aims to build five Rs 100 cr-plus brands and launch products from South African arm in domestic market
Company in May 2014 had invested $1.5 million to acquire 14.6% stake in Chase Pharmaceuticals
Shares of Cipla today closed at Rs 517.50 per scrip on BSE, up 0.49% from the previous close
The acquisition of InvaGen and Exelan will boost Cipla's US business which currently accounts for 8% of its revenue